TY - JOUR
TI - Histone Deacetylases and their Inhibitors in Colorectal Cancer Therapy: Current Evidence and Future Considerations.
AU - Garmpis, Nikolaos
AU - Damaskos, Christos
AU - Garmpi, Anna
AU - Nonni, Afroditi
AU - Georgakopoulou, Vasiliki E.
AU - Antoniou, Efstathios
AU - Schizas, Dimitrios
AU - Sarantis, Panagiotis
AU - Patsouras, Alexandros
AU - Syllaios, Athanasios
AU - Vallilas, Christos
AU - Koustas, Evangelos
AU - Kontzoglou, Konstantinos
AU - Trakas, Nikolaos
AU - Dimitroulis, Dimitrios
JO - Current Medicinal Chemistry
PY - 2021
VL - null
TODO - null
SP - null
PB - 
SN - 0929-8673
TODO - 10.2174/0929867328666210915105929
TODO - *Inhibitors, *Histone, *HDAC, *Colorectal Cancer, *Deacetylase, *Epigenetics, *HDACI, *Targeted Therapy
TODO - Colorectal cancer (CRC) comprises a heterogeneous group of gastrointestinal tract tumors. It is a multifactorial disease, and a plethora of distinct factors are  involved in its pathogenesis and pathophysiology. The development of CRC is not  limited to genetic changes, but epigenetic and environmental factors are also  involved. Among the epigenetic factors, histone deacetylases (HDACs), a group of  epigenetic enzymes that regulate gene expression, have been reported to be  over-expressed in CRC. HDACs and their inhibitors seem to play an important role in  the molecular pathophysiology of CRC. The aim of this review was to define the role  of HDAC inhibitors as potential anticancer agents against CRC.
ER -